GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » Shiller PE Ratio

Curis (CRIS) Shiller PE Ratio : (As of Apr. 11, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Curis Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Curis Shiller PE Ratio Historical Data

The historical data trend for Curis's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Shiller PE Ratio Chart

Curis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Curis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Curis's Shiller PE Ratio

For the Biotechnology subindustry, Curis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Curis's Shiller PE Ratio falls into.


;
;

Curis Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Curis's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Curis's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-1.25/133.1571*133.1571
=-1.250

Current CPI (Dec. 2024) = 133.1571.

Curis Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -30.000 99.621 -40.099
201506 -6.000 100.684 -7.935
201509 -4.000 100.392 -5.306
201512 -10.000 99.792 -13.343
201603 -7.000 100.470 -9.277
201606 -9.000 101.688 -11.785
201609 -21.000 101.861 -27.452
201612 -8.000 101.863 -10.458
201703 -11.000 102.862 -14.240
201706 -9.800 103.349 -12.627
201709 -10.600 104.136 -13.554
201712 -4.400 104.011 -5.633
201803 -6.600 105.290 -8.347
201806 -5.200 106.317 -6.513
201809 -4.400 106.507 -5.501
201812 -3.600 105.998 -4.522
201903 -6.000 107.251 -7.449
201906 -4.400 108.070 -5.421
201909 -3.800 108.329 -4.671
201912 -5.200 108.420 -6.386
202003 -5.600 108.902 -6.847
202006 -3.400 108.767 -4.162
202009 -2.200 109.815 -2.668
202012 -2.200 109.897 -2.666
202103 -2.200 111.754 -2.621
202106 -2.400 114.631 -2.788
202109 -2.400 115.734 -2.761
202112 -3.000 117.630 -3.396
202203 -3.600 121.301 -3.952
202206 -3.400 125.017 -3.621
202209 -2.830 125.227 -3.009
202212 -2.400 125.222 -2.552
202303 -2.390 127.348 -2.499
202306 -2.470 128.729 -2.555
202309 -2.130 129.860 -2.184
202312 -2.030 129.419 -2.089
202403 -2.050 131.776 -2.071
202406 -2.030 132.554 -2.039
202409 -1.700 133.029 -1.702
202412 -1.250 133.157 -1.250

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Curis  (NAS:CRIS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Curis Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Curis's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Curis Business Description

Traded in Other Exchanges
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Executives
Jonathan B. Zung officer: CDO C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Kenneth I Kaitin director C/O TUFTS CNTR FOR THE STUDY OF DRUG DEV, 75 KNEELAND ST, SUITE 1100, BOSTON MA 02111
Martyn D Greenacre director 41 MOORES ROAD, FRAZER PA 19355
Robert Martell officer: Head of Research & Development 4 MAGUIRE ROAD, LEXINGTON MA 02421
Diantha Duvall officer: CFO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James E Dentzer director, officer: President & CEO C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
William Steinkrauss officer: VP, Finance & Treasurer, other: Principal Accounting Officer C/O CURIS, INC.,, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Lori Anne Kunkel director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Fattaey Ali Ph.d. officer: President & COO C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Aurigene Discovery Technologies Ltd 10 percent owner 39-40 KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD, BANGALORE (KARNATAKA) K7 560100
David Tuck officer: Sr. Vice-President C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421